Tempus Technology

AI-enabled assistant for providers and researchers that enables rapid insights.

• Retrieve patient information

  Quickly access patient information, like report status, results on actionable biomarkers, and MSI/TMB status.

• Identify relevant up-to-date clinical trials

  Discover the latest clinical trials based on specific patient enrollment criteria so your patients can be screened quickly.

• Define a research cohort using natural language

  Easily build a data cohort incorporating rich molecular biomarkers and therapies, without coding experience.

• Accelerate time to insights with generative AI

  Explore unstructured clinical data like adverse events or reported symptoms, and easily create cohort and prevalence summations without sifting through individual patient records.

Suite of applications that live inside EHRs.

• Seamless EHR ordering and result delivery

  Place orders and receive results, directly in your EHR.

• Unlock structured genomic data

  Discrete genomic data can power your decision-making, advanced analytics, and clinical research.

• Refresh therapies and clinical trials

  Refresh therapies and clinical trials available for your patients based on previous test results – all inside your EHR.

A central platform for researchers and scientists to find, access, and analyze Tempus data.

• Explore cohorts of interest

  Apply Inclusion and Exclusion criteria to generate cohorts of interest using our AI assistant.

• Refine and visualize

  Gain insight from quick no-code analyses with Lens Analytical Apps.

• Analyze to uncover critical insights

  Leverage RWD in a flexible computational environment with Lens Workspaces, using R and Jupyter Notebooks.

AI-enabled insights from medical images.

• Automated quantification

  Segments and measures lesions of interest, providing accurate contours and long-axis and short-axis measurements.

• Automated tracking

  Links lesions across time points to create longitudinal tracking reports to calculate lesion response automatically.

• Automated reporting

  Automates therapy response criteria and generates a comprehensive report that can be linked to the patient record in the EMR or Tempus Hub.

Identify and close gaps in care.

• Patient identification

  Identifies patients and contextualizes where they are in the care journey relative to clinical guidelines.

• Notifications in workflow

  Uses tiered and customized notifications driven by physician preferences.

• Tracking across the care continuum

  Tracking for patients who need timely management, lists to search for subsets of patients, and dashboards for real-time insights into a hospital’s patient population.

Our genomic profiling services encompass a broad range of sequencing options, allowing for data-driven patient decisions.

• xT CDx: 648-gene tissue-based NGS-based test for molecular profiling of all malignant solid tumors, that includes assessment of MSI status, and companion diagnostic (CDx) claims for colorectal cancer (CRC) patients.¹
• xT: 648 gene DNA sequencing panel for solid tumors only (includes heme malignancies).
• xR: Whole-transcriptome RNA sequencing panel (includes heme malignancies).
• xF/xF+: 105/523 ctDNA sequencing panel.
• xG/xG+: 52/88 gene panel for hereditary cancers.
• xE: Whole exome, 19,000+ gene DNA sequencing panel.
• xM for MRD: Tumor-naive MRD test for recurrence monitoring in colorectal cancer patients.
• xM (NeXT Personal® Dx): Tumor-informed MRD test for recurrence monitoring in NSCLC and breast cancer, as well as response monitoring for IO therapy. (Test by Personalis).

1. xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status, using DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens, from previously diagnosed cancer patients with solid malignant neoplasms.The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling. Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product. xT CDx is a single-site assay performed at Tempus Labs, Inc., Chicago, IL. For the complete xT CDx label, including companion diagnostic indications and important risk information, please visit tempus.com/xt-cdx-label/

Gain additional insights across multiple cancer types through our algorithmic testing options.

• IPS: Prognostic biomarker for immune checkpoint inhibitor candidates.
• HRD: Measures homologous recombination deficiency.
• TO: Refines diagnosis for cancers with uncertain origins.
• DPYD: Identifies patients at elevated risk for toxicity to 5 FU and/or capecitabine.
• UGT1A1: Identifies patients at elevated risk for toxicity to irinotecan, sacituzumab govitecan, and/or belinostat.
• PurIST℠: Classifies pancreatic ductal adenocarcinomas into one of two subtypes (basal-like or classical).